Company news

Hunan Warrant Pharmaceutical Co., Ltd. news in 2026

Hunan Warrant Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate

November 10, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Receipt of the Approval Notice for the Marketing Application for an API

November 5, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Report for Q3 2026

October 30, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Notice on Convening the 1st Extraordinary General Meeting in 2026

October 30, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Obtaining of the Approval Notice for Its API Marketing Application

October 30, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Resolutions of the 7th Meeting of the 4th Board of Directors

October 30, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Purchase of Equity Interests and Related Party Transaction

October 30, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Profit Distribution Plan for the First Three Quarters of 2026

October 30, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Change of Registered Capital, Amendment to the Articles of Association, Filing of Industrial and Commercial Registration Changes, and Amendment to Certain Corporate Governance Policies

October 30, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing

October 28, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Receipt of the Approval Notice for the Marketing Application for an API

October 16, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of the Subsidiary's Obtaining of the Approval Notice for Its API Marketing Application

October 13, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate

September 29, 2026

(688799)"Hunan Warrant Pharmaceutical Co., Ltd."Announcement on Shareholding Reduction Plan of Senior Executive

September 27, 2026

Announcement on Changes in the Equity Structure of the Controlling Shareholder

September 27, 2026

Announcement on Change in Equity Interests of Controlling Shareholder and Its Persons Acting in Concert Reaching 1% Threshold and Result of Shareholding Reduction by Controlling Shareholder and Completion of Implementation of the Change in Shareholding Method by Controlling Shareholder's Partner

September 18, 2026

Indicative Announcement on Change in Equity Interests of the Controlling Shareholder and Its Person Acting in Concert Reaching 1% Threshold

September 17, 2026

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

September 8, 2026

Announcement on Voluntary Disclosure of the Subsidiary's Obtaining of the Approval Notice for Its API Marketing Application

September 2, 2026

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate

August 31, 2026

Indicative Announcement on Shareholding Reduction Plan of Controlling Shareholder and Proposed Change of Shareholding Form by the Controlling Shareholder's Partner

August 25, 2026

Announcement on Increasing Cash Management Limit for Temporarily Idle Self-owned Funds

August 24, 2026

Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement

August 3, 2026

Announcement on Progress in Providing Guarantee for Wholly-owned Sub-subsidiary

July 22, 2026

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Supplementary Application

July 17, 2026

Announcement on Change of Business Scope and Completion of Industrial and Commercial Change Registration by Controlling Shareholder

July 14, 2026

Voluntary Disclosure Announcement on the Inclusion of the Company's Products in the National Essential Medicines List

July 10, 2026

Announcement on Implementation of Dividend Distribution for 2025

June 24, 2026

Announcement on Adjusting Amount of Dividends per Share in 2025 Annual Profit Distribution Plan

June 5, 2026

Announcement on Voluntary Disclosure of Notice on Listing Application Approval for the Subsidiary's Active Pharmaceutical Ingredient

June 2, 2026

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate

June 1, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 29, 2026

Announcement on Voluntary Disclosure of Subsidiary Passing GMP Compliance Inspection for Drugs

May 22, 2026

Announcement on Changing Venue of the 2025 Annual General Meeting

May 21, 2026

Announcement on Progress in Providing Guarantee for Wholly-owned Sub-subsidiary

May 13, 2026

Announcement on Changes in Equity Structure of Controlling Shareholders

April 28, 2026

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

April 27, 2026

Announcement on Adjusting Grant Price and Amount in 2024 Restricted Stock Incentive Plan

April 20, 2026

Announcement on a Controlling Shareholder Adding a Person Acting in Concert and the Completion of Internal Transfer of Shares by Agreement Among Persons Acting in Concert

April 7, 2026

Indicative Announcement on a Controlling Shareholder Adding a Person Acting in Concert and the Internal Transfer of Shares by Agreement Among Persons Acting in Concert, Resulting in Change of Equity

March 24, 2026

Announcement on Voluntary Disclosure of Subsidiary Passing On-site Inspection by FDA

March 15, 2026

Announcement on Voluntary Disclosure of Subsidiary Passing ANVISA GMP Certification

February 27, 2026

Announcement on Preliminary Earnings Estimate for 2025

February 13, 2026

Announcement on Voluntary Disclosure of Selection of Products for Continuation Procurement Under National Procurement Scheme After Agreement Expiry

February 12, 2026

Announcement on Voluntary Disclosure of Receipt by the Joint-stock Company of the Phase I Clinical Study Report for ZG-002 Tablets

February 5, 2026

Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License

January 28, 2026

Announcement on Voluntary Disclosure of Withdrawal of Drug Registration Application

January 27, 2026